Welcome to the 4th Macrophage-directed Therapies Summit
Supercharging Small Molecule, Antibody, Oligonucleotide & Cell-Based Therapies
The Macrophage-directed Therapies Summit is returning for the 4th year, back to Boston - and continues to be the leading industry-focused forum uniting this emerging community of over 100 leaders to review cutting-edge advances in the discovery, preclinical, translational, and clinical development of macrophage-directed therapies.
Covering discovery to the clinic and a brand-new Biomarkers Bootcamp, the summit is returning with two tracks of content.
Join the likes of Gilead Sciences, Pionyr Immunotherapeutics, KAHR Medical, Codiak BioSciences, Ichnos Sciences, and Enlivex Therapeutics Ltd, and receive the latest updates on clinical progress, novel approaches, and targets to broaden the spectrum of macrophage targeting. With continuing growth in the macrophage space, delve into:
- CD47 targeting and other ‘don’t eat me’ signals
- Safety concerns due to model translatability and dosing
- Optimal combination or monotherapy discovery
Learn from our expert speaker faculty, who will be sharing more exclusive new or unpublished insights than ever before.
Turbocharge macrophage applications from oncology, inflammation, and beyond
Listen to leaders in the field as they share clinical data in the hope of validating macrophage-directed therapies and boosting funding in the space
Optimize and advance models and translatability to accelerate transfer into the clinic
Enhance safety and clinical operations by improving dosing strategy and determining optimal combinations while considering monotherapy
Review alternative methods to controlling macrophages through macrophage repolarization, CAR-Macrophages, exosome-mediated genetic reprogramming, and more
Explore how the interactions between macrophages and other cells can boost the efficacy
2022 Expert Speaker Faculty
